Survival of patients with primary osteosarcoma and lung metastases
Li, W.; Zhang, S.
Journal of BUON Official Journal of the Balkan Union of Oncology 23(5): 1500-1504
2018
ISSN/ISBN: 1107-0625 PMID: 30570878 Document Number: 694976
To investigate the survival of patients with primary osteosarcoma and lung metastases. Clinical data of 128 patients with primary osteosarcoma and lung metastases who were admitted to Shenzhen Second People's Hospital from January 2013 to January 2015, were enrolled and retrospectively analyzed. Follow-up lasted for 3 years and after follow-up, patients were divided into survival group (n=54) and death group (n=74) according to their survival status. Univariate and logistic multivariate analyses were conducted on related factors contributing to death in patients with primary osteosarcoma and lung metastases. At the end of follow-up, there were 74 deaths (death group) and 54 survivors (survival group). Among all 128 patients, the 6-month, 1-year, 2-year and 3-year survival rates were 96.87, 92.96, 61.71 and 42.18%, respectively . Univariate analysis showed that tumor diameter, histological subtype, visceral pleural involvement, the number of lung metastatic lesions, the outcome after chemotherapy for the primary tumor, and therapy for lung metastasis were closely associated with death in patients with primary osteosarcoma and lung metastases (p<0.05). Multivariate logistic regression analysis showed that chondrocytes, multiple lung metastatic lesions, poor outcome after chemotherapy for primary tumor, and no surgery-combined treatment for lung metastasis were risk factors contributing to death in patients with primary osteosarcoma and lung metastases (p<0.05). Risk factors contributing to death in patients with primary osteosarcoma and lung metastases include chondrocytes, multiple lung metastatic lesions, poor outcome after chemotherapy for primary tumor, and no surgery-combined treatment for lung metastasis. Surgical resection and preoperative adjuvant chemotherapy can effectively improve the patient survival.